A phase II randomized placebo-controlled study of AZD8931, an inhibitor of EGFR, HER2, and HER3 signaling, plus paclitaxel (P) vs P alone in patients (pts) with low HER2-expressing advanced breast cancer (BC) (THYME) Meeting Abstract
| Authors: | Baselga, J.; Hegg, R.; Losada, M. V.; Vidaurre, T.; Lluch, A.; Petrakova, K.; Mann, H.; Ghiorghiu, S.; Stuart, M.; Landers, D.; Thress, K.; Klinowska, T.; Cortes, J. |
| Abstract Title: | A phase II randomized placebo-controlled study of AZD8931, an inhibitor of EGFR, HER2, and HER3 signaling, plus paclitaxel (P) vs P alone in patients (pts) with low HER2-expressing advanced breast cancer (BC) (THYME) |
| Meeting Title: | 104th Annual Meeting of the American Association for Cancer Research (AACR) |
| Journal Title: | Cancer Research |
| Volume: | 73 |
| Issue: | 8 Suppl. |
| Meeting Dates: | 2013 Apr 6-10 |
| Meeting Location: | Washington, DC |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2013-04-15 |
| Language: | English |
| ACCESSION: | WOS:000331220601085 |
| DOI: | 10.1158/1538-7445.am2013-lb-146 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LB-146 -- 104th Annual Meeting of the American-Association-for-Cancer-Research (AACR) -- APR 06-10, 2013 -- Washington, DC -- 1 -- Source: Wos |
